Two clinical isolates of Vibrio alginolyticus from New Jersey are reported, one from a mixed stump infection and the other grown in pure culture from the conjunctival discharge of a man with conjunctivitis. The biochemical characteristics and antibiotic susceptibilities of these two isolates are presented. Human infections caused by V. alginolyticus are reviewed.
MATERIALS AND METHODS Case 1. A 43-year-old white man was hospitalized in October 1978 for pneumococcal pneumonia with positive blood culture. He was a heavy drinker and worked as a fish cutter. On admission, he was noticed to have markedly infected conjunctivae with purulent discharge from the left eye. A culture of this discharge revealed pure growth of V. alginolyticus. He was treated with procaine penicillin intramuscularly and sulfisoxazole eye drops with rapid response.
Case 2. A 57-year-old white man was admitted in
October 1978 for a stump ulcer. He had a below-knee amputation for a traumatic injury 17 (13) , Japan (17, 23, 24) , Hawaii (1, 12) , and North America (1, 2, 5, 14, 21) . Recent exposure to seawater usually antedates the isolation of V. alginolyticus from humans, although infrequently such a history cannot be obtained (7, 12, 18, 22) . An example of the latter is the second patient described in this report.
As shown in Table 3 , the feces, skin, and ear account for most human isolates of V. alginolyticus reported in the English literature. In Japan it has been isolated from stool specimens in 0.5% of healthy people during the summer months due to ingestion of contaminated raw seafood; this stool carriage is not associated with clinically evident intestinal infection (17, 24) . The majority of nonfecal isolates have been from patients with skin infections, including ulcers, (1, 2, 7, 11, 12, 15, 22) . V. alginolyticus has rarely been recovered from sputum and an eye socket (2). Ocular infection due to this organism is extremely rare (18) . One of the patients described in this report had conjunctivitis that was almost certainly due to this organism, which was presumably acquired through his occupation as a fish cutter. In most reports the pathogenic role of V. alginolyticus was not well defined. The organism was usually found in mixed flora (7, (12) (13) (14) 22) , although often in seemingly significant numbers (5, 12, 13, 18) . There are, however, several infections that have been associated with the isolation of V.
alginolyticus in pure culture (11, 12, 14, 15 (9, 11, 22) , often with response to no (13) or only local (12, 14) therapy, a striking contrast to the pathogenic potential of other halophilic vibrios (3, 9) .
VOL. 10, 1979 on October 10, 2017 by guest http://jcm.asm.org/
Downloaded from
If antibiotic therapy is indicated, it should be based on in vitro susceptibility testing. The organism has been found to be resistant to the penicillins and vancomycin, variably sensitive to erythromycin, cephalothin, and colistin, and sensitive to tetracycline, chloramphenicol, trimethoprim-sulfamethoxazole, and gentamicin (5, 7, 8, 11, 12, 14, 15, 18) .
The microbiological criteria generally relied on to distinguish V. alginolyticus from other Vibrio species, including V. parahaemolyticus and lactose-positive vibrios, are the following: (i) growth in 10 g of sodium chloride per dl; (ii) swarming on agar; (iii) positive Voges-Proskauer reaction; and (iv) fermentation of sucrose (3, 12, 14, 16, 20, 23) . However, several fecal isolates from Japan (24) and 7 of 14 isolates described in the second edition of the Manual of Clinical Microbiology (6) were intolerant of high sodium chloride concentrations. The two isolates described in this report failed to grow in 8 to 10% sodium chloride. Swarming on agar has been described also for V. parahaemolyticus (20) and is not a constant feature of V. alginolyticus (19) , and nonmotile strains have been described (7, 19) . Sucrose fermentation also may vary (19, 20) , so that the accepted criteria for identification of V. alginolyticus can be lacking or minimal, thus making identification as to species difficult for clinical microbiology laboratories.
